23.4 C
New York
Thursday, June 11, 2026

Tag: protein

Mama’s Creations Reports First Quarter Fiscal 2027 Financial Results

First Quarter Revenue Grows 50% to $52.8 Million; Net Income Increases 66% to $2.1 Million with Adjusted EBITDA Up 71% to $4.9 Million; Cash Position Grows to $24.4 Million

/C O R R E C T I O N — PEET’S COFFEE INC./

In the news release, PEET'S COFFEE LAUNCHES NATIONWIDE SEARCH FOR ITS FIRST-EVER "CHIEF PLAYLIST OFFICER" TO BEAT AMERICA'S 3PM SLUMP, issued 03-Jun-2026 by PEET'S...

AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT

AG1 Pro's advanced formula builds on AG1's clinically-backed formula to include additional research-backed key ingredients, including creatine, that target muscle strength, metabolic resilience, and...

Saputo Issues its 2026 Promise Report

MONTRÉAL, June 08, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Saputo Inc. (TSX: SAP) (we, Saputo or the Company) issued its 2026 Saputo Promise Report, which highlights progress in key Environmental, Social, and Governance (ESG) priorities that support operational resilience, disciplined long-term growth, and sustainable value creation.

Soules Kitchen Declares June 7th (6/7) the Official Day of Delightful Dinners

TYLER, Texas, June 7, 2026 /PRNewswire/ -- While the world spent the last few years debating the meaning of "67," the team at Soules Kitchen...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver

Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...

“Premium Pet Supplies Expo 2026” Officially Opens

Exotic Pets Steal the Spotlight with Debut Reptilia Carnival and Live Insect Exhibition Featuring Over 50 SpeciesHONG KONG, June 5, 2026 /PRNewswire/ -- Organized...

- A word from our sponsors -

spot_img
HomeTagsProtein